Researchers at the University of Colorado Boulder are studying the unique metabolic adaptations of pythons to identify potential therapies for human heart disease and metabolic disorders. By analyzing how these snakes rapidly expand and shrink their organs and resist muscle atrophy during extreme fasting, scientists have identified a specific blood molecule, pTOS, that shows potential as an appetite suppressant for weight management.
Cardiac Remodeling and Human Heart Health
Pythons exhibit a remarkable ability to rapidly increase the size of their heart and other organs following a large meal to accommodate the metabolic demands of digestion. According to research from the lab of geneticist Leslie Leinwand at the CU Boulder BioFrontiers Institute, this process is entirely reversible. Unlike human hearts, which can become permanently enlarged and stiff due to chronic hypertension or heart failure, the python heart returns to its baseline size after the metabolic surge subsides.
Molecular biologist Jack Gugel, formerly of the Leinwand lab, notes that understanding the signals driving this reversible growth could offer insights into reversing pathological heart conditions in humans. Furthermore, research led by Yuxiao Tan has identified that python cardiac muscle cells can increase in number after feeding. This contrasts with human heart tissue, which typically forms non-functional scar tissue following a myocardial infarction rather than regenerating muscle cells.
Resisting Muscle Atrophy During Fasting
One of the most distinct physiological traits of pythons is their capacity to endure months of fasting without experiencing significant loss of muscle mass or function. Leslie Leinwand reports that this ability is unparalleled in other species, suggesting that the molecular mechanisms behind this preservation could inform future treatments for age-related muscle atrophy in humans. By investigating how pythons maintain muscle tone despite prolonged inactivity and caloric restriction, researchers aim to uncover biological pathways that could protect human muscle health.
The Role of the pTOS Molecule in Metabolism
A study published in the journal Nature Metabolism this year identified a specific molecule, pTOS, which circulates in the blood of Burmese and ball pythons. Research led by the Leinwand team, including Jack Gugel, found that concentrations of this molecule surge up to a thousand-fold after the snake consumes a meal.
Laboratory testing indicates that pTOS acts as an appetite suppressant by targeting the hypothalamus in the brain. In studies involving obese mice, the administration of this molecule resulted in reduced food intake and subsequent weight loss. This discovery has led to the formation of Arkana Therapeutics, a company co-founded by researchers including Leslie Leinwand, Jack Gugel, Tommy Martin, and Jonathan Long of Stanford University, to explore the development of pTOS and other bioactive molecules into clinical treatments.
Lessons from Evolutionary Biology
The approach of utilizing extreme animal physiology for medical discovery is not unprecedented. The development of GLP-1 receptor agonists, such as the weight-loss medication Ozempic, was derived from research on the venom of the Gila monster.
Evolutionary biologists, such as Jasmin Camacho of the Stowers Institute for Medical Research, emphasize that these "natural experiments" have been occurring for millions of years. By studying species that have evolved to thrive in extreme conditions—such as pythons that manage massive metabolic shifts or bats that consume high-sugar diets without developing diabetes—scientists can identify potent, evolutionarily perfected molecules. As Ashley Zehnder, CEO of Fauna Bio, observes, this strategy expands the drug discovery pipeline by looking toward the broader tree of life to solve persistent human health challenges.